The objectives of this panel are threefold: first, to update and inform any stakeholder in the Medical Device and Diagnostic ecosystem on current practices involving the usage of HTA reports by procurement decision makers based on a systematic literature review conducted by MD&D SIG members and gaps in knowledge – how procurement uses (or does not use) HTA, and whether HTA uses procurement for their respective decision-making processes. Second, foster an active discussion of research plans to address these knowledge gaps through survey of stakeholders and offer joining this discussion an opportunity to engage in this future research. Third; to engage the panelists and audience how this interaction should evolve going forward. This forum will leave 20 minutes for open discussion after introductory comments from the speakers. Group discussion will be encouraged.

Background: HTA for MedTech often does not lead to a funding mandate despite being a very robust manner of technology evaluation. When done correctly, HTA considerations include clinical, economic, and societal value to multiple stakeholder groups. There are isolated pockets where funding is attached to HTA, this is far from the norm. Therefore, the role of HTA for MedTech has often been questioned, despite a clear acknowledgement of the value of HTA in health systems. Conversely, estimates suggest that approximately 70% of all medical technologies reach the end user (physicians and patients) through some form of public procurement process. However, most procurement decisions are still predominantly price driven. Initiatives such as value-based procurement, where the procurement decisions are made on clinical improvement and reduced total costs suggest HTA could be a very valuable resource for procurement decision making. We will discuss this paradigm in the context of an ISPOR MD&D SIG working group special project literature review and the future initiative to survey of HTA and procurement stakeholders.